Vimarsana
Biggest News Aggregation in the World

Page 4 - Single Pills News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Single Pills. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Single Pills Today - Breaking & Trending Today

EQS-News: APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential Seite 1 - Vimarsana News

EQS-News: APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential Seite 1

12.04.2023 - EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential 12.04.2023 / 07:30 ... Seite 1

EQS-News: APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 Seite 1 - Vimarsana News

EQS-News: APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 Seite 1

14.02.2023 - EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 14.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the ... Seite 1

EQS-News: APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill - Vimarsana News

EQS-News: APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill

EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA extends portfolio for the treatment of hypertension and hype...

APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensin - Vimarsana News

APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensin

EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill 31.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA extends portfolio for the tr...

APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets - Vimarsana News

APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets

EQS-News: APONTIS PHARMA AG / Key word: 9 Month figures/Quarterly / Interim Statement APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill... | November 10, 2022